112 related articles for article (PubMed ID: 38587073)
1. Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study.
Berg T; Jensen MB; Celik A; Talman ML; Misiakou MA; Knoop AS; Nielsen FC; Ejlertsen B; Rossing M
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38587073
[TBL] [Abstract][Full Text] [Related]
2. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
[TBL] [Abstract][Full Text] [Related]
3. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
[TBL] [Abstract][Full Text] [Related]
5. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
6. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting.
Erber R; Angeloni M; Stöhr R; Lux MP; Ulbrich-Gebauer D; Pelz E; Bankfalvi A; Schmid KW; Walter RFH; Vetter M; Thomssen C; Mayr D; Klauschen F; Sinn P; Sotlar K; Stering K; Stenzinger A; Wunderle M; Fasching PA; Beckmann MW; Hoffmann O; Kimmig R; Harbeck N; Wuerstlein R; Ferrazzi F; Hartmann A
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955851
[TBL] [Abstract][Full Text] [Related]
8. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
[TBL] [Abstract][Full Text] [Related]
9. PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.
Wang L; Li Q; Aushev VN; Neugut AI; Santella RM; Teitelbaum S; Chen J
Breast Cancer; 2021 Nov; 28(6):1235-1242. PubMed ID: 34003448
[TBL] [Abstract][Full Text] [Related]
10. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
Viale G; de Snoo FA; Slaets L; Bogaerts J; van 't Veer L; Rutgers EJ; Piccart-Gebhart MJ; Stork-Sloots L; Glas A; Russo L; Dell'Orto P; Tryfonidis K; Litière S; Cardoso F;
Breast Cancer Res Treat; 2018 Jan; 167(1):123-131. PubMed ID: 28929359
[TBL] [Abstract][Full Text] [Related]
12. Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.
Madera S; Chervo MF; Chiauzzi VA; Pereyra MG; Venturutti L; Izzo F; Roldán Deamicis A; Guzman P; Dupont A; Roa JC; Cenciarini ME; Barchuk S; Figurelli S; Lopez Della Vecchia D; Levit C; Lebersztein G; Anfuso F; Castiglioni T; Cortese E; Ares S; Deza EG; Gercovich FG; Proietti CJ; Schillaci R; Cordo Russo RI; Elizalde PV
Horm Cancer; 2020 Oct; 11(5-6):218-239. PubMed ID: 32632815
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
[TBL] [Abstract][Full Text] [Related]
15. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
17. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies.
Prat A; Chaudhury A; Solovieff N; Paré L; Martinez D; Chic N; Martínez-Sáez O; Brasó-Maristany F; Lteif A; Taran T; Babbar N; Su F
J Clin Oncol; 2021 May; 39(13):1458-1467. PubMed ID: 33769862
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
19. 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Gerstenhauer M; Brockhoff G; Ortmann O
Breast Cancer Res Treat; 2015 Oct; 153(3):647-58. PubMed ID: 26369534
[TBL] [Abstract][Full Text] [Related]
20. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
